FY2026 · ended May 31, 2026 · Revenue $320.17M, +9.5% YoY · Filed Jul 14, 2026
AngioDynamics, Inc. (ANGO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2026, which ended May 31, 2026, it reported revenue of $320.2 million and a net loss of $36.7 million. Free cash flow was $508,000. As of Aug 31, 2026 it held $34.0 million in cash and investments and $7.3 million in total debt.
Revenue (TTM)
$325.38M
+8.2% vs year-ago TTM
Net income (TTM)
$-32.94M
-2.6% vs year-ago TTM
Operating cash flow (TTM)
$3.67M
+147.2% vs year-ago TTM
Free cash flow (TTM)
$1.44M
+112.1% vs year-ago TTM
EPS (TTM)
$-0.79
-0.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
42.05M
+1.7% vs prior year
Net cash
$26.72M
as of Aug 31, 2026
Operating margin
-11.2%
FY 2027
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ANGO (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Latham, NY
- SEC filer status
- Accelerated filer
- SEC CIK
- 1275187
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 May 31, 2026 |
FY 2025 May 31, 2025 |
FY 2024 May 31, 2024 |
FY 2023 May 31, 2023 |
FY 2022 May 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $320.2M | $292.5M | $303.9M | $338.8M | $316.2M |
| Operating income | -$39.9M | -$40.0M | -$192.4M | -$51.2M | -$28.5M |
| Net income | -$36.7M | -$34.0M | -$184.3M | -$52.4M | -$26.5M |
| Diluted EPS | -$0.88 | -$0.83 | -$4.59 | -$1.33 | -$0.68 |
| Operating cash flow | $3.1M | -$10.1M | -$28.2M | $78,000 | -$7.2M |
| Free cash flow | $508,000 | -$14.6M | -$30.7M | -$3.7M | -$11.5M |
| Total assets | $267.2M | $280.1M | $317.7M | $532.6M | $552.8M |
| Total liabilities | $96.3M | $97.2M | $112.1M | $154.3M | $128.3M |
| Stockholders' equity | $170.8M | $183.0M | $205.6M | $378.3M | $424.5M |
| Cash and investments | $53.9M | $55.9M | $76.1M | $44.6M | $28.8M |
| Total debt | $11.0M | $10.1M | $5.9M | $55.1M | $7.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 8, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Oct 8, 2026 | Oct 2, 2026 |
| 10-K/A | Amended annual report | Sep 29, 2026 | May 31, 2026 |
| 10-K/A | Amended annual report | Sep 29, 2026 | May 31, 2026 |
| 10-K | Annual report | Jul 14, 2026 | May 31, 2026 |
All 1002 AngioDynamics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.